Company Overview and News

 
First Capital Realty: Development Pipeline Will Provide A Long Runway Of Growth

2018-09-26 seekingalpha
First Capital Realty is one of Canada's leading owners, developers, and operators of grocery-anchored and retail-focused urban properties.
FCR.DB.H FCR.DB.I FCRGF FCR.DB.J FCR FCR.DB.E

61
10 Best Stocks Under $10

2018-09-20 investorplace
Good things come in small packages goes the saying. Nowhere is that truer than in the markets where stocks under $10 grow to be $100 and possibly even $1,000 over time.
REG FCR.DB.H FCR.DB.I WETF BXG VAC FCR.DB.J AY DXJ FSC GZT OAK HEDJ OSLE JILL SIRI ARCO AMZN FCR.DB.E MCD BBX IBN AQN OCSL FCRGF GZT ICICIBANK FSCFL EDE 532174 FCAP FCR TRVG FSCE

3
Gazit-Globe to Delist Ordinary Shares from the Toronto Stock Exchange

2018-09-13 globenewswire
TEL AVIV, Israel, Sept. 13, 2018 (GLOBE NEWSWIRE) -- Gazit-Globe (NYSE/TSX/TASE: GZT), a leading global real estate company focused on ownership, management and development of retail and mixed use properties in urban markets, announced today that it has applied to the Toronto Stock Exchange (the “TSX”) to have its ordinary shares delisted from the TSX at the close of business on September 27, 2018.
FCR.DB.H FCR.DB.I FCRGF GZT FCR.DB.J GZT DTK FCR FCR.DB.E

3
Gazit-Globe to Delist Ordinary Shares from the Toronto Stock Exchange

2018-09-13 globenewswire
TEL AVIV, Israel, Sept. 13, 2018 (GLOBE NEWSWIRE) -- Gazit-Globe (NYSE/TSX/TASE: GZT), a leading global real estate company focused on ownership, management and development of retail and mixed use properties in urban markets, announced today that it has applied to the Toronto Stock Exchange (the “TSX”) to have its ordinary shares delisted from the TSX at the close of business on September 27, 2018.
FCR.DB.H FCR.DB.I FCRGF GZT FCR.DB.J GZT DTK FCR FCR.DB.E

 
Israeli real estate firm Gazit-Globe to de-list from Toronto exchange

2018-09-13 reuters
* Gazit-Globe , Israel’s largest real-estate company, said on Thursday it had filed an application with the Toronto Stock Exchange (TSX) to de-list its shares from the TSX effective Sept. 27.
FCR.DB.H FCR.DB.I FCRGF FCR.DB.J DTK FCR FCR.DB.E

3
Gazit Globe Completes a NIS 416 million (US$ 115 million) Offering of Unsecured Debentures

2018-09-05 globenewswire
TEL-AVIV, Israel, Sept. 05, 2018 (GLOBE NEWSWIRE) -- Gazit Globe (NYSE; TSX; TASE: GZT), a leading global real estate company focused on the ownership, management and development of retail and mixed use properties in major urban markets, announced today it has completed a public offering of its existing Series M debentures in Israel. The total gross proceeds from the offering were approximately NIS 416 million (approximately US$ 115 million).
FCR.DB.H FCR.DB.I FCRGF GZT FCR.DB.J GZT DTK FCR FCR.DB.E

3
Gazit Globe comunica seu resultado do segundo trimestre de 2018

2018-08-22 globenewswire
TEL-AVIV, Israel, Aug. 22, 2018 (GLOBE NEWSWIRE) -- A Gazit Globe (NYSE/TSX/TASE: GZT), empresa líder global do setor imobiliário, focada na propriedade, administração e no desenvolvimento de propriedades de varejo e uso misto em mercados urbanos, anunciou hoje seus resultados financeiros para o segundo trimestre e seis meses (“Período”) encerrado em 30 de junho de 2018.
FCR.DB.H FCR.DB.I FCRGF GZT FCR.DB.J GZT FCR FCR.DB.E

3
Gazit Globe Reports its Results for the Second Quarter 2018

2018-08-21 globenewswire
TEL-AVIV, Israel, Aug. 21, 2018 (GLOBE NEWSWIRE) -- Gazit Globe (NYSE/TSX/TASE: GZT), a leading global real estate company focused on the ownership, management and development of retail and mixed use properties in urban markets, announced today its financial results for the second quarter and six months ("Period") ended June 30, 2018.
FCR.DB.H FCR.DB.I FCRGF GZT FCR.DB.J GZT DTK FCR FCR.DB.E

 
RioCan: Retail Segment Appears To Be Stabilizing

2018-08-18 seekingalpha
Its current projects under development will increase its net leasable area by 5.8% and increase its net asset value.
FCR.DB.H FCR.DB.I FCRGF FCR.DB.J SCC FCR FCR.DB.E SRSCQ SRSC

 
First Capital Realty Inc. (FCRGF) CEO Adam Paul on Q2 2018 Results - Earnings Call Transcript

2018-08-05 seekingalpha
First Capital Realty Inc. (OTCPK:FCRGF) Q2 2018 Earnings Conference Call August 2, 2018 2:00 PM ET
CHOO FCR.DB.H FCR.DB.I FCRGF CDNTF FCR.DB.J CDNAF FCAP JYMHF FCR FCR.DB.E

 
First Capital Realty Inc. 2018 Q2 - Results - Earnings Call Slides

2018-08-03 seekingalpha
The following slide deck was published by First Capital Realty Inc. in conjunction with their 2018 Q2 earnings call.
FCR.DB.H FCR.DB.I FCRGF FCR.DB.J FCR FCR.DB.E

3
Gazit Globe Announces Date for Q2 2018 Results Conference Call

2018-07-31 globenewswire
TEL-AVIV, Israel, July 31, 2018 (GLOBE NEWSWIRE) -- Gazit Globe (NYSE/TSX/TASE: GZT), a leading global real estate company focused on the ownership, management and development of retail and mixed use properties in urban markets, invites you to participate at 10:00 am US EDT/ 5:00 pm Israel Time on Tuesday, August 21, 2018 in a live conference call with senior management to discuss the Company’s 2nd quarter results ended June 30, 2018.
FCR.DB.H FCR.DB.I FCRGF GZT FCR.DB.J GZT DTK FCR FCR.DB.E

3
Gazit Globe Divests of its Remaining Investment in Regency Centers Corporation for Approximately USD 502 Million (NIS 1.83 billion)

2018-07-26 globenewswire
TEL-AVIV, Israel, July 26, 2018 (GLOBE NEWSWIRE) -- Gazit Globe (NYSE/TSX/TASE: GZT), a leading global real estate company focused on the ownership, management and development of retail and mixed use properties in urban markets, announced that on July 25, 2018, wholly-owned subsidiaries of the Company sold 5.6 million shares of common stock of Regency Centers Corporation (NYSE:REG) (“Regency”), for approximately $61.
REG FCR.DB.H FCR.DB.I FCR.DB.J GZT DTK EQIT FCRGF GZT FCR FCR.DB.E EQY

3
GAZIT GLOBE (GZT):  A Quality Global Shopping Center REIT That Is Reasonably Priced

2018-07-17 seekingalpha
This REIT sells at about 55% of its fair value while paying a 4.5% dividend yield.
REG FCR.DB.H FCR.DB.I FCR.DB.J GZT DTK EQIT FCRGF GZT FRT FCAP FCR FCR.DB.E EQY

62
10 Best Stocks Under $10

2018-07-11 investorplace - 1
Good things come in small packages goes the saying. Nowhere is that truer than in the markets where stocks under $10 grow to be $100 and possibly even $1,000 over time.
REG FCR.DB.H FCR.DB.I WETF BXG VAC FCR.DB.J AY DXJ FSC GZT OAK HEDJ OSLE JILL SIRI ARCO AMZN FCR.DB.E MCD BBX IBN AQN OCSL FCRGF GZT ICICIBANK FSCFL EDE 532174 FCAP FCR TRVG FSCE

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...